Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Archive of Views

<< 2012 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2014 >>

25 January 2013: UCL Enterprise – your views

Stephen Caddick, Vice-Provost (Enterprise), and his colleagues would like to hear your views on UCL Enterprise – its mission, its relevance and your experience and involvement. More...

<< 2012 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2014 >>